The first phase I/II clinical trial (ClinicalTrials.gov ref. NCT01461213) for CHM commenced in 2011, employing the AAV2/2 expressing REP1 in 14 CHM patients via subretinal administration.147, 148. The gene discussed is CHM; the disease is choroideremia.